Great post @kervio, this is a continuation of our conversation the other day (you have explained beautifully).
The question the analysis raises (or unknown at this point) is whether or not the SOC improvements in survival rates will also be seen in the Rem-L group?
- Based on Mt Sinai I think the figs were 83% survival (17% mortality) for Rem-L.
- The SOC has moved from 88% mortality to 35% mortality
- If we get only (for example) a 25% improvement in our mortality rate due to the general SOC improvement
- The new (Rem-L) mortality percentage would 12.75% (down from 17%) ie only 9 deaths in 68 achieving the p<0.0001 (or overwhelming efficacy at the 45% readout)
I don't know whether the general improvements in SOC would translate into an improvement in both groups, it is however, a potential upside for earlier overwhelming efficacy.
Maybe someone else could answer that?
- Forums
- ASX - By Stock
- MSB
- Overwhelming efficacy - the stats required
MSB
mesoblast limited
Add to My Watchlist
0.93%
!
$1.63

Overwhelming efficacy - the stats required, page-8
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B |
Open | High | Low | Value | Volume |
$1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 707 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 7320 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 707 | 1.630 |
3 | 51200 | 1.625 |
15 | 159486 | 1.620 |
3 | 75310 | 1.615 |
11 | 90509 | 1.610 |
Price($) | Vol. | No. |
---|---|---|
1.635 | 7000 | 1 |
1.640 | 17668 | 3 |
1.645 | 20972 | 3 |
1.650 | 37309 | 4 |
1.655 | 45000 | 3 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online